

# Spine Stereotactic Body **Radiotherapy to Three or More Contiguous Vertebral Levels**

# OPEN ACCESS

#### Edited by:

Chia-ho Hua. St. Jude Children's Research Hospital, United States

#### Reviewed by:

Sunyoung Jang, Princeton Radiation Oncology Center, United States Chia-Lin Tsena. University of Toronto, Canada Anupam Rishi, Moffitt Cancer Center, United States

#### \*Correspondence:

Joshua D. Palmer Joshua.Palmer@osumc.edu

<sup>†</sup>These authors share first authorship

#### Specialty section:

This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology

Received: 04 April 2022 Accepted: 16 May 2022 Published: 08 June 2022

#### Citation:

Dibs K, Blakaj DM, Prasad RN, Olausson A, Bourekas EC, Boulter D, Ayan AS, Cochran E, Marras WS, Mageswaran P, Thomas E, Lee H, Grecula J, Raval RR, Mendel E, Scharschmidt T. Lonser R. Chakravarti A, Elder JB and Palmer JD (2022) Spine Stereotactic Body Radiotherapy to Three or More Contiguous Vertebral Levels. Front, Oncol. 12:912804. doi: 10.3389/fonc 2022 912804

Khaled Dibs<sup>1†</sup>, Dukagjin M. Blakaj<sup>1†</sup>, Rahul N. Prasad<sup>1</sup>, Alexander Olausson<sup>1</sup>, Eric C. Bourekas<sup>2</sup>, Daniel Boulter<sup>2</sup>, Ahmet S. Ayan<sup>1</sup>, Eric Cochran<sup>1</sup>, William S. Marras<sup>3</sup>, Prasath Mageswaran<sup>3</sup>, Evan Thomas<sup>1</sup>, Hyeri Lee<sup>1</sup>, John Grecula<sup>1</sup>, Raju R. Raval<sup>1</sup>, Ehud Mendel<sup>4</sup>, Thomas Scharschmidt<sup>5</sup>, Russell Lonser<sup>6</sup>, Arnab Chakravarti<sup>4</sup>, James B. Elder<sup>6</sup> and Joshua D. Palmer<sup>1\*</sup> <sup>1</sup> Department of Radiation Oncology, The James Cancer Hospital at the Ohio State University Wexner Medical Center,

Columbus, OH, United States, <sup>2</sup> Department of Radiology, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, United States, <sup>3</sup> Spine Research Institute, Department of Biomedical Engineering, College of Engineering, The Ohio State University, Columbus, OH, United States, <sup>4</sup> Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States, <sup>5</sup> Department of Orthopedic Surgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, GA, United States, <sup>6</sup> Department of Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, GA, United States

Background: With survival improving in many metastatic malignancies, spine metastases have increasingly become a source of significant morbidity; achieving durable local control (LC) is critical. Stereotactic body radiotherapy (SBRT) may offer improved LC and/or symptom palliation. However, due to setup concerns, SBRT is infrequently offered to patients with  $\geq$ 3 contiguous involved levels. Because data are limited, we sought to evaluate the feasibility, toxicity, and cancer control outcomes of spine SBRT delivered to  $\geq$ 3 contiguous levels.

Methods: We retrospectively identified all SBRT courses delivered between 2013 and 2019 at a tertiary care institution for postoperative or intact spine metastases. Radiotherapy was delivered to 14-35 Gy in 1-5 fractions. Patients were stratified by whether they received SBRT to 1-2 or ≥3 contiguous levels. The primary endpoint was 1year LC and was compared between groups. Factors associated with increased likelihood of local failure (LF) were explored. Acute and chronic toxicity was assessed. In-depth dosimetric data were collected.

Results: Overall, 165 patients with 194 SBRT courses were identified [54% were men, median age was 61 years, 93% had Karnofsky Performance Status (KPS) ≥70, and median follow-up was 15 months]. One hundred thirteen patients (68%) received treatment to 1-2 and 52 to 3-7 (32%) levels. The 1-year LC was 88% (89% for 1-2 levels vs. 84% for  $\geq$ 3 levels, p = 0.747). On multivariate analysis, uncontrolled systemic disease was associated with inferior LC for patients with  $\geq 3$  treated levels. No other

June 2022 | Volume 12 | Article 912804

1

demographic, disease, treatment, or dosimetric variables achieved significance. Rates of new/progressive fracture were equivalent (8% vs. 9.5%, p = 0.839). There were no radiation-induced myelopathy or grade 3+ acute or late toxicities in either group. Coverage of  $\geq$ 95% of the planning target volume with  $\geq$ 95% prescription dose was similar between groups (96% 1–2 levels vs. 89%  $\geq$ 3 levels, p = 0.078).

**Conclusions:** For patients with  $\geq$ 3 contiguous involved levels, spine SBRT is feasible and may offer excellent LC without significant toxicity. Prospective evaluation is warranted.

Keywords: local control, multilevel, postoperative, radiosurgery, spine metastases, stereotactic body radiation therapy, stereotactic radiotherapy, toxicity

# INTRODUCTION

Spine metastases are a common source of morbidity for patients with cancer, as resultant pain and neurologic dysfunction can significantly diminish quality of life (1). Thus, radiation therapy (RT) ± surgery is frequently indicated for improved local control (LC) and/or symptom palliation (1). Historically, conventional external beam radiation therapy (EBRT) was considered the standard of care for patients requiring palliative RT. However, stereotactic body radiotherapy (SBRT) has recently been shown to offer significantly improved LC and motor function, particularly for patients with radioresistant tumor histologies (2-6). While the prospective phase III trial RTOG 0631 demonstrated that SBRT can be safely and accurately delivered to 2 contiguous vertebral levels using image-guided radiotherapy (IGRT) (7), there are limited data evaluating the feasibility of SBRT to  $\geq 3$  spinal levels. One concern is that small setup errors (particularly rotational) could be magnified when treating  $\geq 3$  levels resulting in tumor undercoverage or increased dose to critical neural structures such as the spinal cord and cauda equina (8). However, modern treatment techniques such as 6-degree-offreedom (6-DOF) couch tops, full-body immobilization, and cone-beam computed tomography (CBCT) may allow reproducible and accurate SBRT delivery within 1 mm even when targeting  $\geq 3$  contiguous vertebral levels (9). If so, the LC, symptom palliation, and decreased toxicity benefits of SBRT could be extended to appropriately selected patients with  $\geq 3$  contiguous involved levels who currently are frequently offered conventional EBRT. To demonstrate the feasibility of multilevel spine SBRT, we compared LC, dosimetric, and toxicity data of patients who received treatment to  $\geq 3$  contiguous spinal levels to those receiving SBRT to just 1-2 levels.

# METHODS

### Study Design

We retrospectively evaluated patients with spine metastases treated with SBRT at a single tertiary care institution from 2013 to 2019. Patients who underwent surgical resection or stabilization before SBRT were eligible for inclusion. Patients with cervical, thoracic, lumbar, or sacral metastases were included. Pertinent patient demographic and disease characteristics were collected including, but not limited to, age, gender, performance status defined using Karnofsky Performance Status (KPS), tumor histology, systemic disease control, receipt of concurrent systemic therapy, site of spine metastases, Spinal Instability Neoplastic Score (SINS), and Bilsky grade. Concurrent systemic therapy was defined as systemic therapy given within 2 weeks of RT. For patients undergoing surgery, the type of surgical intervention was documented. Pertinent information regarding RT was collected including, but not limited to, prescribed dose and fractionation and the size of the planning target volume (PTV). Biologically effective doses (BEDs) were calculated using  $\alpha/\beta$  ratios of 10 for the tumor and 2 for the spinal cord and cauda equina. Using these BED values, dosimetric data were collected including, but not limited to, the minimum and maximum doses to the PTV, dose received by 95% of the PTV (D95%) and D90%, and max point doses to the spinal cord and cauda equina, where applicable. This study was approved by our institutional review board.

### Treatment

All patients underwent spine magnetic resonance imaging (MRI) prior to surgery or spine SBRT (General Healthcare 1.5 Tesla MR, Chicago, IL, USA, or Siemens Healthcare 1.5T or 3T MR, Erlangen, Germany). Patients who underwent surgery completed additional postoperative MRI and received a computed tomography (CT) myelogram on the same day as simulation for radiation planning. Patients were simulated in the supine position without intravenous contrast (GE Discovery CT590RT, Chicago, IL, USA). A thermoplastic frameless mask was used for immobilization of the cervical spine. A stereotactic body frame and vac loc bag were used to immobilize patients for the treatment of the thoracic, lumbar, and/or sacral spine. For accurate delineation of target volumes and organs at risk, spine MRI sequences, including but not limited to, axial and sagittal T1 postcontrast and T2, were fused to the CT simulation. For patients receiving postoperative SBRT, both preoperative imaging and postoperative imaging were fused as was the CT myelogram.

The clinical target volume (CTV) included gross osseous and extraosseous disease plus bony anatomy at risk of harboring microscopic disease as per consensus contouring guidelines for both postoperative and definitive spine SBRT (10, 11). Regardless of the number of treated levels, the PTV was equivalent to the CTV (no expansion). The spinal cord was delineated on the

postsurgery CT myelogram or the MRI T2 axial series for nonoperative patients with a 2-mm circumferential expansion to create a planning risk volume (PRV) avoidance structure. SBRT was prescribed at a dose of 14–35 Gy in 1–5 fractions and normalized with the goal that at least 95% of the PTV received the prescription dose. Spinal cord constraints were based on the The American Association of Physicists in Medicine (AAPM) TG 101 recommendations appropriate for the chosen treatment fractionation (12). Volumetric modulated arc therapy with coplanar arcs utilizing 6 or 10 megavoltage beams was predominantly used for treatment planning (Eclipse version 16, Varian Medical Systems, Palo Alto, CA, USA). Treatments were delivered on a linear accelerator (Varian TrueBeam, Palo Alto, CA, USA) with 6-DOF and daily CBCT to minimize setup uncertainty.

## **Study Endpoints**

The primary study endpoint was the rate of LC at 1 year. LC was assessed using follow-up MRIs of the treated spine that occurred every 3 months post-SBRT. Patients were also followed with clinic appointments at that interval with a detailed history and physical exam. Radiographic tumor response was assessed as per SPIne response assessment in Neuro-Oncology recommendations (13). Serial MRI concerning radiographic evidence of progression was retrospectively reviewed for confirmation of local failure (LF) by two independent neuroradiologists. Serial imaging was routinely used to differentiate between progression and pseudoprogression based upon evolution over time. Where available, perfusion sequences were also utilized. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and rates of acute and chronic toxicity. PFS was defined as the time from the start of SBRT to the time of progression, death, or last follow-up. OS was defined as the time from the start of SBRT to the time of death or last follow-up. Acute and chronic toxicities were defined as per the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. The proportion of plans where 95% of the PTV was covered by at least 95% of the prescription volume was also assessed to investigate the feasibility of multilevel spine SBRT.

# **Statistical Analysis**

Patients were stratified into two groups. Group A consisted of patients who received SBRT to 1-2 contiguous levels, while group B included patients with  $\geq 3$  contiguous treated levels. Continuous and discrete variables were compared between groups using the Mann-Whitney U and Pearson's chi-square tests, respectively (14). Median follow-up was calculated using the reverse Kaplan-Meier (KM) method. KM curves were used to assess the endpoints of OS, PFS, and LC. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with a twosided significance threshold of 0.05. For analysis, dosimetric variables were dichotomized by the median. Univariate analysis (UVA) was performed using a proportional hazards model to assess for a significant relationship between clinically relevant variables and improved LC. Cox proportional hazards modeling multivariate analyses (MVAs) were then performed using variables that achieved significance on UVA and/or clinically relevant factors to examine for an association with

increased likelihood of LF. All statistical analyses were performed using SPSS Statistics version 27 (IBM, Armonk, NY, USA).

# RESULTS

# Patient Demographic and Treatment Characteristics

Overall, 165 patients with 194 metastatic spine sites treated with SBRT with a median follow-up of 15 months (range: 1-72 months) were identified (Table 1). Among them, 54% of the patients were men, the median patient age at treatment was 61 (range: 24-93) years, and 93% of patients had a KPS >70. In this study, 32% of patients underwent separation surgery. In addition, 24% and 8% of patients underwent vertebrectomy and laminectomy, respectively. SBRT was offered for improved LC (through delivery of higher BED) in radioresistant histology, pain, ablation of oligometastatic disease, or oligoprogression in 44%, 36%, 11%, and 9% of patients, respectively. The thoracic spine (65%) was the most treated site. A total of 113 patients (68%) received treatment at 1-2 contiguous levels, and 52 (32%) received SBRT at 3-7 contiguous levels. The most prescribed regimen was 27 Gy in 3 fractions. The most common histologies treated were renal cell carcinoma (RCC) (31%), non-small cell lung cancer (NSCLC) (13%), and breast cancer (11%). Moreover, 45% of patients received concurrent systemic therapy, which was most frequently chemotherapy (20%) or immunotherapy (13%).

With respect to patients with 1–2 treated levels, patients with  $\geq$ 3 irradiated levels were more likely to have received a surgical intervention (61% vs. 21%, p = 0.001), have received fractionated SBRT rather than single-fraction radiosurgery (94% vs. 80%, p = 0.007), have a larger PTV (150 vs. 52 cc, p = 0.001), have progressive systemic disease (30% vs. 18%, p = 0.001), and have an SINS score greater than 7 (50% vs. 25%, p = 0.001) and a higher Bilsky grade (p = 0.001). Patients with  $\geq$ 3 irradiated levels were more likely to have breast, prostate, head and neck, or sarcoma histologies and less likely to have NSCLC or RCC (p = 0.04). There was no significant difference between groups by gender, age, receipt of systemic therapy, or performance status.

# Local Control and Survival Outcomes

The cumulative incidence of LF for the whole cohort at 6, 12, and 18 months was 6%, 12%, and 18%, respectively (**Figure 1**). When stratified by the number of contiguous levels treated, there was no difference in 1-year rates of LF (11% for 1–2 levels vs. 16% for  $\geq$ 3 levels, p = 0.747, **Figure 2**). In patients who experienced LF, time to failure did not differ between groups (9.8 for 1–2 levels vs. 7.6 months for  $\geq$ 3, p = 0.873). On UVA, no demographic or disease characteristics significantly predicted improved LC in patients with  $\geq$ 3 treated levels (**Table 2**). On MVA, male gender [HR 2.734 (CI: 1.047–7.142), p = 0.040] and stable systemic disease at the time of SBRT were associated with better LC [HR 4.154 (CI: 1.667–10.355), p = 0.002] for these patients with multiple contiguous treated levels (**Table 3**). No other demographic or disease variables achieved significance. The 1-year OS and PFS for this cohort were 62% and 56%, respectively.

ABLE 1   Patient demographic and treatment characteristics stratified by the number of contiguous treated spinal levels.
--

194         100         54           Notice of Discuss () Montrial         15 (1-72)         15 (2-72)         15 (1-43)         0.628           Mediar Page (Wantria)         15 (1-72)         15 (2-72)         15 (1-43)         0.628           Gendar         0         22 (243)         0.628         0.628           Kornan         104 (6+74)         72 (6+3)         32 (6+74)         0.244           Kornan         100 (6x73)         12 (6+15)         32 (6+75)         0.244           Kornan         100 (6x73)         12 (6+15)         32 (6+75)         0.244           Straps         70%         24 (775)         24 (753)         0.21 (753)         0.01 (753)           Straps         70 (756)         24 (753)         24 (753)         0.01 (753)         0.01 (753)           Nonio         15 (35-60)         0.27 (753)         27 (1-43)         0.00 (754)	Variable	All	1-2 levels	3–7 levels	p value
Number of balancis         155         113         62           Moder of Oversy (Morth)         15 (1-77)         15 (2-43)         05	Number of Courses	194	140	54	
Modul Age (Yenna)         15 [1-72]         15 [2-72]         15 [24-87]         61 [24-87]         69 [24-87]         69 [24-87]         69 [24-87]         69 [24-87]         69 [25 [69]         55 4           Mon         104 (49)         72 (15)         32 (69)         63 (69)         63 (69) <td< td=""><td>Number of Patients</td><td>165</td><td>113</td><td>52</td><td></td></td<>	Number of Patients	165	113	52	
Median Age Yannil         B1 (24–83)         61 (24–87)         61 (24–87)         62 (48-93)           Man         104 (474)         72 (513)         32 (675)         32           Kann Carlow         180 (483)         72 (513)         32 (675)         32           C70%         180 (483)         122 (475)         21 (475)         22 (475)           C70%         17 (478)         12 (475)         21 (475)         0000           C70%         17 (478)         10 (475)         21 (478)         0000           Carlow         17 (478)         10 (478)         10 (478)         0000           Median Presoritation Dasse (56)         27 (15–53)         27 (14–28)         0.700           Median Presoritation Dasse (56)         21 (27-64)         61 (43–63)         0.303           Median Presoritation Dasse (57)         51 (23–62)         61 (32–62)         61 (32–62)         0.507           Median Presoritation Dasse (57)         52 (50–64)         62 (63–64)         62 (63–64)         0.303           Median Presoritation Dasse (57)         52 (50–64)         63 (63–64)         63 (63–64)         0.307           Median Presoritation Dasse (57)         52 (50–64)         63 (63–64)         0.307         0.307           Sympol Con	Median Follow-up (Months)	15 (1–72)	15 (2–72)	15 (1–63)	0.873
Gandar	Median Age (Years)	61 (24–93)	61 (24–87)	61 (24–93)	0.986
Man         104 (54%)         72 (51%)         82 (54%)           Kamotsky Parlimanos Status         0.294         52 (65%)         22 (41%)         0.294           270%         10 (19%)         12 (9%)         2 (45%)         0.298           270%         10 (19%)         12 (9%)         2 (45%)         0.001           270%         10 (19%)         10 (19%)         0.101         0.001           Variaboactomy         10 (19%)         21 (14-53)         27 (14-52)         0.716           None         110 (19%)         21 (14-53)         27 (14-52)         0.716           Madian Privactificatio Date (54)         51 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)         52 (32-63)	Gender				0.534
Women90, 46%)68, 46%)22, 47%)270%180, 63%)128, 19%)52, 40%)470%12, 19%)2, 47%)6.00%Surgery0.00%21, 19%)2, 47%)Unitabulatory16, 65%)6, 47%)10, 10%%)None131, 16%)10, 10%%)21, 19%30.078Markin DEED* (50)27, 114-56%64, 110, 10%%)21, 19%30.078Markin DEED* (50)27, 114-56%64, 112-56%64, 112-56%0.078Markin DEED* (50)27, 114-56%64, 112-56%28, 112-56%0.078Markin DEED* (50)26, 104-66%64, 102-66%0.027Markin DEED* (50)26, 104-66%26, 00-660.026Markin DEED* (50)51, 122-62%61, 102-62%0.027Markin DEED* (50)50, 105-11%40, 60-600.026Markin DEED* (50)50, 105-11%40, 60-600.026Markin DEED* (50)50, 105-11%40, 60-600.026Markin DEED* (50)50, 105-11%40, 60-600.026Markin DEED* (50)50, 105-11%40, 60-600.027Markin DEED* (50)50, 105-11%40, 60-600.027Markin DEED* (50)50, 105-11%40, 60-600.027Markin DEED* (50)50, 105-11%0.0270.026Markin DEED* (50)50, 1050.0260.026Markin DEED* (50)50, 1050.0260.026Markin DEED* (50)50, 1050.0260.026Markin DEED* (50)50, 1050.026<	Men	104 (54%)	72 (51%)	32 (59%)	
Kanobis/Patriannace Status	Women	90 (46%)	68 (49%)	22 (41%)	
270%128 (B%)128 (B%)22 (B%)2 (A%)StrageryTC.001<	Karnofsky Performance Status				0.294
<70%12 (2%)2 (2%)0.001Vartabeactarny47 (24%)0.4 (17%)2.5 (24.2%)0.001None151 (65%)110 (79%)2.7 (14-36)2.7 (14-36)2.7 (14-36)0.7 (05.36)Modian Prescripton DEBD (5%)0.5 (17.5-00)0.5 (25.5-00)0.5 (25.5-0)0.	≥70%	180 (93%)	128 (91%)	52 (96%)	
Surgery	<70%	14 (7%)	12 (9%)	2 (4%)	
Verdencedomy         16 (8%)         64 (4%)         10 (194)           None         131 (8%)         110 (70%)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         27 (14-30)         28 (14-30)         0.279           Median Prescription DED' (Sy)         30 (11-52)         31 (12-52)         28 (11-44)         0.232           Median Prov Doris, BED' (Gy)         51 (23-62)         51 (33-63)         51 (23-62)         51 (33-63)         0.032           Median Prov Doris, BED' (Gy)         52 (30-64)         52 (30-64)         52 (30-64)         0.328         0.337           Median Prov Doris, BED' (Gy)         50 (10-114)         46 (9-69)         57 (10-14)         0.332           Median Spinal Core Max EED'' (Gy)         52 (30-64)         12 (03-64)         63 (18-0)         0.037           TV Converage by 328% Prescription Dose         12 (29,6)         64 (34)         6 (143)         0.079           Single         13 (19%)         13 (19%)         14 (29,6)         6 (143)         0.071           Median Totolocccccccccccccccccccccccccccccccccc	Surgery				0.001
Lambactomy         16 (8%)         6 (4%)         10 (19%)           None         31 (1983)         110 (79%)         21 (14-28)         0.700           Median Prescription Does (Gy)         51 (37.3-00)         51 (37.3-00)         51 (37.3-00)         50.3-50         0.279           Median Provintion BED* (Gy)         54 (37-00)         54 (37-00)         54 (37-00)         54 (37-00)         54 (37-00)         52 (37-30)         53.3-50         0.279           Median PV DotSK BED* (Gy)         52 (32-04)         52 (33-62)         52 (35-34)         0.383           Median PV DotSK BED* (Gy)         52 (32-64)         52 (35-64)         0.23 (35-64)         0.23 (35-64)         0.23 (35-64)         0.23 (35-64)         0.32 (35-64)<	Vertebrectomy	47 (24%)	24 (17%)	23 (42%)	
None         131 (88%)         110 (72%)         21 (80%)           Median Prescription DEDr (Vo)         51 (33-60)         27 (14-38)         27 (14-38)         0.700           Median Prescription DEDr (Vo)         51 (33-60)         51 (33-60)         0.279           Median Prescription DEDr (Vo)         51 (25-62)         58 (35-66)         0.228           Median Prescription SEDr (Vo)         51 (25-62)         51 (25-62)         0.572           Median Prescription Mes EDr (Vo)         52 (20-64)         52 (20-64)         52 (20-64)         0.28 (31-94)         0.382           Median Prescription Mes EDr (Vo)         50 (10-114)         46 (96%)         57 (10-114)         0.328           Median Prescription Mes EDr (Vo)         72 (5-144)         79 (5-144)         68 (31-94)         0.327           PV Coverage Vortige Mes EDr (Vo)         72 (5-144)         79 (5-144)         0.328         0.007           Stription EDr (Vo)         12 (8%)         16 (9%)         6 (11%)         0.007           Stription EDr (Vo)         12 (8%)         15 (29%)         0.007           Stription EDr (Vo)         12 (8%)         15 (29%)         0.007           Median Treated Volume (cc)         65 (6-670)         22 (20-86)         15 (29%)           Median Tr	Laminectomy	16 (8%)	6 (4%)	10 (19%)	
Median Prescription Dase (sy)         27 (14-38)         27 (16-39)         27 (14-28)         0.700           Median Prescription DBSP (sy)         51 (37.5-90)         51	None	131 (68%)	110 (79%)	21 (39%)	
Median Prescription BED' (%)         51 (33-80)         51 (37-5-00)         51 (33-80)         0.279           Median PTV Mean BED' (%)         64 (44-80)         54 (37-80)         64 (44-80)         0.330           Median PTV D69% BED' (%)         51 (26-82)         51 (26-82)         0.572           Median PTV D69% BED' (%)         52 (30-84)         52 (30-84)         52 (30-84)         0.326           Median Spinal Cond Max BED'' (%)         52 (10-114)         46 (9-90)         57 (10-114)         0.326           PTV Coverage tot Max BED'' (%)         72 (5-144)         74 (5-144)         58 (31-94)         0.327           Median Spinal Cond Max BED'' (%)         72 (5-144)         74 (5-144)         58 (31-94)         0.327           PTV Coverage tot 255% Prescription Dose         182 (94%)         154 (95%)         61 (94%)         0.007           Single         12 (9%)         6 (49%)         151 (94%)         0.007         0.007           Median Trastati Volume (cc)         65 (6-670)         22 (6-482)         150 (29-670)         0.001           Median Tot Max         10 (5%)         12 (9%)         11 (9%)         10 (9%)         6 (49%)         11 (9%)         0.007           Median Tot Max         10 (5%)         12 (9%)         11 (9%)         <	Median Prescription Dose (Gy)	27 (14–35)	27 (15–35)	27 (14–28)	0.700
Madian PTV Manimum BED' (sy)         30 (11-62)         31 (12-62)         22 (11-44)         0.282           Madian PTV Mash BED' (sy)         51 (26-62)         51 (26-52)         0.572           Madian PTV Mosh BED' (sy)         52 (06-41)         62 (28-64)         52 (20-54)         0.388           Madian PTV Dosh BED' (sy)         50 (10-114)         46 (9-9)         57 (10-114)         0.327           Madian PTV Mosh BED' (sy)         52 (10-14)         76 (5-144)         58 (31-94)         0.327           PTV Coverage by 265% Prescription Dose         182 (94%)         112 (90%)         6 (11%)         0.327           Not Mat         163 (94%)         12 (95%)         6 (49%)         6 (11%)         0.007           Softs PTV Coverage by 265% Prescription Dose         182 (94%)         12 (90%)         51 (94+8)         0.007           Madian Text Mathema ED'         163 (94%)         12 (90%)         51 (94+8)         0.007           Madian Text Volume (cc)         65 (94-70)         62 (94-70)         0.001         0.001           Madian Text Volume (cc)         65 (94%)         12 (90%)         51 (94+8)         0.009           Seriontext Volume (cc)         65 (13%)         12 (94%)         0 (17%)         0.000           Read Carcinoma	Median Prescription BED* (Gy)	51 (33–60)	51 (37.5–60)	51 (33–56)	0.279
Median PTV Meri PEV Meri PEV Meri PEV Meri PEV Meri PEV DeVis EED" (sy)         51 (24–62)         51 (25–52)         51 (26–52)         50 (26–54)         0.383           Median PTV DeVis EED" (sy)         52 (30–64)         52 (26–64)         52 (26–54)         0.382           Median Spial oxid Max EED" (Gy)         50 (10–114)         46 (9–69)         57 (10–114)         0.328           Median Cauda Equita Max EED" (Gy)         72 (5–144)         79 (5–144)         58 (31–34)         0.387           PV Coverage Vs 255% Prescription Dose         152 (94%)         134 (96%)         6 (11%)         26 (11%)         0.387           PV Coverage Vs 255% Prescription Dose         152 (94%)         134 (96%)         16 (11%)         0.387           PV Coverage Vs 255% Prescription Dose         152 (94%)         16 (94%)         112 (96%)         1 (94%)           Practionatic         63 (6–670)         52 (6–86)         150 (29–670)         0.001           HeitopathOdy         112 (94%)         112 (95%)         1 (94%)         1 (95%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)         1 (94%)<	Median PTV Minimum BED* (Gy)	30 (11–52)	31 (12–52)	28 (11–44)	0.262
Median PPV D693% BED' (6y)         51 (26-62)         51 (26-62)         52 (26-64)	Median PTV Mean BED* (Gy)	54 (34–69)	54 (37–69)	54 (34–63)	0.393
Median Priv D60% BED' (Gy)         52 (30-64)         52 (30-64)         52 (30-54)         0.038           Median Spinal Oxt Max EED''' (Gy)         72 (5-144)         78 (5-144)         58 (31-94)         0.327           PV Coverage V         0.078         0.078         0.078         0.078           255% PV Coverage V: 255% Prescription Dose         152 (94%)         13 4 (96%)         48 (93%)         0.078           255% PV Coverage V: 255% Prescription Dose         152 (94%)         12 (95%)         3 (95%)         0.007           Srigle         31 (16%)         28 (20%)         5 (94%)         0.007           Mult         163 (84%)         112 (95%)         5 (94%)         0.001           Histogathology         7         7         0.001           Breast         22 (11%)         13 (95%)         9 (17%)         0.001           Breast         22 (11%)         13 (95%)         9 (17%)         0.001           Nort media Carcinoma         10 (37%)         11 (95%)         7 (13%)         11 (95%)           Sarcoma         19 (95%)         12 (95%)         7 (13%)         11 (95%)         12 (95%)         12 (95%)         12 (95%)         12 (95%)         12 (95%)         12 (95%)         12 (95%)         12 (95%)	Median PTV D95% BED* (Gy)	51 (26–62)	51 (33–62)	51 (26–52)	0.572
Median Spinal cord Max BED" (0y)         50 (10–114)         46 (8–99)         57 (10–114)         0.327           Median Cauda Equina Max BED" (0y)         72 (5–144)         78 (5–144)         98 (3–94)         0.327           PTV Coverage by 295% Prescription Dose         182 (94%)         134 (96%)         48 (89%)         0.078           Sef% PTV Coverage by 295% Prescription Dose         12 (5%)         6 (4%)         6 (11%)         0.007           Sef% PTV Coverage by 295% Prescription Dose         12 (5%)         6 (4%)         5 (194%)         0.007           Sef% PTV Coverage by 295% Prescription Dose         12 (5%)         6 (4%)         5 (194%)         0.007           Sef% PTV Coverage by 295% Prescription Dose         12 (5%)         6 (4%)         5 (194%)         0.007           Series         13 (5%)         12 (20%)         5 (194%)         0.001           Median Total Ker         2 (11%)         13 (7%)         11 (8%)         2 (2%)           Trycold         13 (7%)         11 (8%)         2 (2%)         6 (17%)           Normand Cell Lung Cancer         4 (5%)         4 (7%)         6 (9%)           Normand Cell Lung Cancer         9 (5%)         3 (25%)         6 (17%)           Normand Cell Lung Cancer         1 (1%)         1 (1%) <td>Median PTV D90% BED* (Gy)</td> <td>52 (30–64)</td> <td>52 (36–64)</td> <td>52 (30–54)</td> <td>0.986</td>	Median PTV D90% BED* (Gy)	52 (30–64)	52 (36–64)	52 (30–54)	0.986
Median Cauda Equina Max EED"" (Cy)         72 (5-144)         78 (5-144)         78 (5-144)         78 (5-144)         78 (5-194)         0.037           295% PV Coverage by 295% Presoription Dose         182 (94%)         134 (96%)         44 (99%)         0.077           Single         12 (9%)         6 (47%)         6 (11%)         0.007           Single         31 (16%)         28 (20%)         3 (9%)         0.007           Mult         163 (84%)         112 (90%)         51 (94%)         0.001           Instant Traated Volume (cc)         65 (6-77)         25 (6-486)         150 (26-77)         0.001           Bread Cal Carcinoma         26 (13%)         45 (62%)         15 (28%)         0.003           Sarcoma         19 (9%)         13 (1%)         9 (17%)         0.001           Sarcoma         19 (9%)         16 (11%)         2 (9%)         16 (12%)           Non-small Cell Lung Carcer         26 (13%)         3 (2%)         6 (12%)         16 (12%)           Non-small Cell Lung Carcer         26 (13%)         3 (2%)         6 (12%)         16 (13%)           Non-small Cell Lung Carcer         9 (5%)         3 (2%)         6 (12%)         16 (13%)           Neuroendocorine         9 (5%)         3 (2%)	Median Spinal cord Max BED** (Gy)	50 (10–114)	46 (9–99)	57 (10–114)	0.326
PTV Coverage by 28% Prescription Dose         128 (24%)         134 (86%)         48 (89%)           Not Mat         12 (6%)         6 (4%)         6 (11%)           Fractionation         3 (16%)         28 (20%)         3 (6%)         0.007           Single         31 (16%)         28 (20%)         3 (6%)         0.007           Mult         163 (84%)         112 (60%)         51 (84%)         0.001           Mattan Teated Volume (cc)         66 (6-70)         26 (6-488)         150 (29-670)         0.001           Hestan Teated Volume (cc)         60 (31%)         45 (23%)         9 (17%)         0.003           Searcoma         00 (31%)         45 (23%)         9 (17%)         0.004           Breast         22 (11%)         13 (8%)         9 (17%)         0.004           Searcoma         00 (31%)         45 (23%)         0 (17%)         0.004           Non-small Cell Lung Cancer         26 (13%)         11 (18%)         2 (28%)         0 (0%)           Non-small Cell Lung Cancer         26 (13%)         14 (3%)         0 (0%)         0.005           Non-small Cell Lung Cancer         26 (13%)         14 (3%)         0 (0%)         0.005           Non-small Cell Lung Cancer         16 (5%)         <	Median Cauda Equina Max BED** (Gy)	72 (5–144)	79 (5–144)	58 (31–94)	0.327
26% PV Coverage by 26% Prescription Dose         12 (26%)         64 (4%)         64 (11%)           Fractionation         6 (4%)         6 (11%)         0.007           Single         31 (16%)         28 (20%)         3 (6%)         0.007           Multi         153 (84%)         112 (80%)         51 (94%)         0.001           Median Treated Volume (cc)         65 (6–670)         22 (6–48)         50 (29–670)         0.001           Breast         22 (11%)         13 (9%)         9 (17%)         56 (6–670)         26 (6–48)         7 (13%)           Bread Cel Carcinoma         00 (31%)         45 (23%)         15 (28%)         7 (13%)           Sarcoma         19 (9%)         12 (1%)         2 (2%)         3 (3%)           Castrointestinal         19 (9%)         11 (1%)         3 (6%)         1 (1%)           Non-small Cell Lung Cancer         26 (13%)         2 (15%)         3 (2%)         0 (0%)           None-small Cell Lung Cancer         9 (5%)         3 (2%)         0 (0%)         4 (1%)           Heat and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         0 (0%)         5 (9%)           Metastotic Parentary         1 (1%)         1 (1%)         0 (0%)         5 (9%)         5 (9%)	PTV Coverage				0.078
Not Met         12 (5%)         6 (4%)         6 (11%)           Fractionation         0.007           Single         31 (19%)         28 (20%)         3 (6%)           Mult         163 (84%)         112 (80%)         51 (94%)           Mult         163 (84%)         112 (80%)         51 (94%)         0.0001           Histopathology         713 (9%)         91 (7%)         0.001           Breast         22 (11%)         13 (9%)         16 (2%)         36 (2%)           Brand Call Carcinoma         60 (31%)         45 (2%)         7 (13%)         10 (9%)           Sarcoma         19 (9%)         16 (11%)         3 (9%)         0 (9%)           Own-small Call Lung Cancer         42 (13%)         6 (12%)         0 (9%)           Noursmall Call Lung Cancer         4 (5%)         3 (2%)         6 (12%)           Metanoma         7 (3%)         6 (4%)         1 (1%)         0 (9%)           Head and Neck Squarnous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)         4 (3%)         4 (7%)         6 (9%)         3 (2%)         6 (12%)         1 (1%)         0 (9%)         5 (2%)         6 (2%)         5 (9%)         5 (2%)         6 (2%)         6 (2%)         6 (3%)	≥95% PTV Coverage by ≥95% Prescription Dose	182 (94%)	134 (96%)	48 (89%)	
Fractionation         Unite         0.007           Single         31 (16%)         28 (20%)         3 (6%)           Mutin         163 (84%)         112 (60%)         51 (94%)           Metican Treated Volume (cc)         65 (6-670)         52 (6-486)         150 (29-670)         0.001           Breast         22 (11%)         13 (9%)         91 (7%)         0.400           Bread Call Carcinoma         60 (31%)         45 (32%)         15 (28%)         3           Sarconna         19 (9%)         12 (9%)         7 (13%)         3           Oxarona         19 (9%)         16 (11%)         3 (6%)         3           Non-smail Cell Lung Cancer         26 (13%)         2 (15%)         5 (9%)         3           Neuroendocrino         4 (2%)         3 (2%)         6 (12%)         4 (3%)         0 (0%)           Head and Nock Squamous Cell Carcinoma         9 (5%)         3 (2%)         0 (0%)         4 (3%)         6 (12%)         4 (3%)         6 (12%)         4 (3%)         0 (0%)         4 (3%)         6 (12%)         4 (3%)         6 (12%)         4 (3%)         6 (12%)         6 (3%)         6 (3%)         6 (3%)         6 (3%)         6 (3%)         6 (3%)         6 (3%)         6 (3%) <t< td=""><td>Not Met</td><td>12 (6%)</td><td>6 (4%)</td><td>6 (11%)</td><td></td></t<>	Not Met	12 (6%)	6 (4%)	6 (11%)	
Single         31 (16%)         28 (20%)         3 (8%)           Multi         163 (84%)         112 (80%)         51 (94%)           Median Treated Volume (cc)         65 (6–670)         52 (6–486)         150 (29–670)         0.001           Instant Treated Volume (cc)         65 (6–670)         52 (6–486)         150 (29–670)         0.001           Breast         22 (11%)         13 (9%)         9 (17%)         7           Sarcoma         60 (31%)         45 (32%)         7 (13%)           Thyroid         13 (9%)         11 (8%)         2 (2%)           Gastrointestinal         19 (9%)         16 (11%)         3 (6%)           Non-smail Ceil Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Non-smail Ceil Lung Cancer         4 (2%)         4 (3%)         6 (12%)           Melandam Neck Squamous Ceil Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastaic Paragangiona         3 (2%)         3 (2%)         0 (0%)           Metastaic Paragangiona         3 (2%)         3 (2%)         0 (0%)           Gastrointestinal         1 (1%)         1 (1%)         0 (0%)           Metastaic Paragangiona         3 (2%)         3 (2%)         6 (12%)	Fractionation				0.007
Multi         152 (84%)         112 (80%)         51 (94%)           Median Treatd Volume (cc)         65 (6-670)         52 (6-486)         150 (29-670)         0.000           Breast         26 (11%)         13 (9%)         9 (17%)         0.000           Breast         26 (11%)         45 (32%)         15 (28%)         5           Sarcoma         19 (9%)         11 (9%)         7 (13%)         3           Thyroid         13 (7%)         11 (9%)         2 (2%)         3           Castrointestinal         19 (9%)         16 (11%)         3 (6%)         3           Non-small Cell Lung Cancer         26 (13%)         2 (11%)         0 (0%)         4           Neuroendocrine         4 (2%)         4 (3%)         0 (0%)         4           Neuroendocrine         9 (5%)         3 (2%)         6 (12%)         4           Metastatic Phitulary         1 (1%)         1 (1%)         0 (0%)         4           Metastatic Phitulary         1 (1%)         1 (1%)         0 (0%)         4           Adenoid Ozstic Carcinoma         3 (2%)         3 (2%)         0 (0%)         5           Metastatic Phitulary         1 (1%)         1 (1%)         0 (0%)         5         5<	Single	31 (16%)	28 (20%)	3 (6%)	
Median Treated Volume (cc)         65 (6-670)         52 (4-86)         150 (29-670)         0.001           Breast         22 (11%)         13 (9%)         9 (17%)         0.001           Breast         22 (11%)         13 (9%)         15 (28%)         0.001           Sarcoma         90 (9%)         45 (23%)         15 (28%)         0.001           Thyroid         13 (9%)         12 (9%)         7 (13%)         0.001           Non-small Cell Lung Cancer         26 (35%)         21 (15%)         3 (9%)         0.00%)           Non-small Cell Lung Cancer         26 (35%)         2 (23%)         0.00%)         0.00%           Neatomothechine         4 (2%)         4 (3%)         0.00%         0.00%           Metanoma         7 (3%)         6 (44%)         1 (1%)         0.00%           Metantic Paraganginoma         3 (2%)         0 (0%)         0.0%           Metantic Paraganginoma         1 (1%)         1 (1%)         0.0%         0.0%           Cenvical Thoracic         1 (1%)         1 (1%)         0 (0%)         0.0%         0.0%           Cenvical Thoracic         8 (5%)         4 (3%)         4 (7%)         0.0%         0.0%           Cenvical Thoracic         8 (5%)	Multi	163 (84%)	112 (80%)	51 (94%)	
Histogy	Median Treated Volume (cc)	65 (6–670)	52 (6–486)	150 (29–670)	0.001
Breast         22 (11%)         13 (9%)         9 (17%)           Brenal Cell Carcinoma         60 (16%)         45 (62%)         15 (28%)           Sarcoma         19 (9%)         12 (9%)         7 (13%)           Thyroid         13 (7%)         11 (18%)         2 (2%)           Castrointestinal         19 (9%)         16 (11%)         3 (6%)           Non-small Cell Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Neuroendocrine         4 (2%)         4 (3%)         0 (9%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         0 (9%)           Metastatic Paraganglioma         3 (2%)         3 (2%)         0 (9%)           Biadder         1 (1%)         1 (1%)         0 (9%)         5 (9%)           Cervical Thoracic         8 (5%)         4 (3%)         4 (7%)         5 (9%)           Cervical Thoracic         8 (5%)         4 (3%)         4 (7%)         5 (9%)           Chenoid Cystic Carcinoma         9 (9%)         3 (3%)         4 (7%)         5 (9%)         6 (16%)         5 (9%) <t< td=""><td>Histopathology</td><td></td><td></td><td></td><td>0.040</td></t<>	Histopathology				0.040
Renal Cell Carcinoma         60 (31%)         45 (22%)         7 (13%)           Sarcoma         19 (9%)         12 (9%)         7 (13%)           Thyroid         13 (7%)         11 (8%)         2 (2%)           Gastrointestinal         19 (9%)         61 (11%)         3 (6%)           Non-small Cell Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Neuroendocrine         4 (2%)         4 (3%)         0 (0%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         0 (0%)           Metastatic Phuitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Pharaganglioma         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Vertebral         22 (10%)         17 (12%)         5 (9%)           Cervical         22 (10%)         17 (12%)         5 (9%)           Cervical         7 (3%)         3 (3%)         4 (7%)           Concurrent Systemic Therapy         7 (3%)         3 (3%)         4 (7%)           Concure	Breast	22 (11%)	13 (9%)	9 (17%)	
Sarcoma         19 (9%)         12 (9%)         7 (13%)           Thyroid         13 (7%)         11 (8%)         2 (2%)           Gastrointestinal         19 (9%)         16 (11%)         3 (6%)           Non-small Cell Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Neuroendocrine         4 (2%)         4 (3%)         0 (0%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastatic Phutary         1 (1%)         1 (1%)         0 (0%)           Metastatic Paragangioma         3 (2%)         3 (2%)         0 (0%)           Salcodel Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site         22 (10%)         17 (12%)         5 (9%)           Cenvical Thoracic         8 (5%)         4 (3%)         4 (7%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Concurrent Systemic Therapy         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         26 (13%)         20 (14%)         6 (15%)	Renal Cell Carcinoma	60 (31%)	45 (32%)	15 (28%)	
Thyoid         13 (7%)         11 (8%)         2 (2%)           Gastrointestinal         19 (9%)         16 (11%)         3 (6%)           Non-small Cell Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Neuroendoorine         4 (2%)         4 (3%)         0 (0%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         0 (0%)           Metastatic Privitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Privitary         3 (2%)         3 (2%)         0 (0%)           Metastatic Privitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Privitary         3 (5%)         3 (2%)         0 (0%)           Vertebral         2 (2 (10%)         1 (1%)         0 (0%)           Vertebral         2 (10%)         4 (3%)         4 (7%)           Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         4 (5(23%)         40 (2%)         6 (15%)           Thoracic         103 (53%)         68 (48%)         5 (28%)           Immunothera	Sarcoma	19 (9%)	12 (9%)	7 (13%)	
Gastrointestinal         19 (9%)         16 (11%)         3 (6%)           Non-small Cell Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Neuroenchoorine         4 (2%)         4 (3%)         0 (0%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastatic Paragangiona         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Cervical         1 (1%)         1 (1%)         0 (0%)           Cervical         1 (1%)         1 (1%)         0 (0%)           Cervical         103 (53%)         4 (3%)         4 (7%)           Cervical         103 (53%)         68 (48%)         35 (65%)           Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         23 (16%)         1 (3%)           Concurrent Systemic Therapy         26 (13%)         20 (14%)         6 (15%)           Immuncherapy	Thyroid	13 (7%)	11 (8%)	2 (2%)	
Non-small Cell Lung Cancer         26 (13%)         21 (15%)         5 (9%)           Neuroendocrine         4 (2%)         4 (3%)         0 (0%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         0 (0%)           Metastatic Praganglioma         3 (2%)         3 (2%)         0 (0%)           Metastatic Praganglioma         3 (2%)         3 (2%)         0 (0%)           Adencid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adencid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Cervical         1 (1%)         1 (1%)         0 (0%)           Cervical         22 (10%)         17 (12%)         5 (9%)           Concid Cystic Carcinoma         103 (53%)         68 (48%)         35 (65%)           Lumbar         7 (3%)         3 (3%)         4 (7%)           Thoracic         103 (53%)         68 (5%)         1 (3%)           Concurrent Systemic Therapy         28 (20%)         23 (16%)         1 (3%)           Concurrent Systemic Therapy         28 (20%)         23 (16%)	Gastrointestinal	19 (9%)	16 (11%)	3 (6%)	
Neuroendocrine         4 (2%)         4 (3%)         0 (0%)           Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastatic Pituitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Paraganglioma         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         2 (10%)         1 7 (12%)         5 (9%)           Cervical         2 (10%)         4 (3%)         4 (7%)           Imbarcic Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (9%)         3 (3%)         4 (7%)           Concurrent Systemic Therapy         26 (13%)         20 (14%)         6 (15%)	Non-small Cell Lung Cancer	26 (13%)	21 (15%)	5 (9%)	
Prostate         9 (5%)         3 (2%)         6 (12%)           Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastatic Pituitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Paraganglioma         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adencid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adencid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Verteral Site	Neuroendocrine	4 (2%)	4 (3%)	0 (0%)	
Melanoma         7 (3%)         6 (4%)         1 (1%)           Head and Neck Squanous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastatic Pituitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Paraganglioma         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site         -         0.572           Cervical         22 (10%)         17 (12%)         5 (9%)           Cervical-Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         23 (16%)         13 (3%)           Concurrent Systemic Therapy         26 (13%)         20 (14%)         4 (7%)           Targeted Therapy         26 (13%)         20 (14%)         4 (7%)           Radioactive Iodine         3 (2%)         3 (2%)         20 (10%)           Thoracic         3 (2%)         3 (2%)         0 (0%)           Immotherapy	Prostate	9 (5%)	3 (2%)	6 (12%)	
Head and Neck Squamous Cell Carcinoma         9 (5%)         3 (2%)         6 (12%)           Metastatic Pituitary         1 (1%)         1 (1%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site         -         0.572         Cervical           Cervical-Thoracic         8 (5%)         4 (3%)         4 (7%)           Concical-Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Readiactive Iodine         3 (2%)         20 (5%)         20 (5%)      <	Melanoma	7 (3%)	6 (4%)	1 (1%)	
Metastatic Pituitary         1 (1%)         1 (1%)         0 (0%)           Metastatic Paraganglioma         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site         0.0%)         0 (0%)           Cervical Thoracic         2 (10%)         17 (12%)         5 (9%)           Concide Thoracic         8 (5%)         4 (3%)         4 (7%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (9%)         8 (5%)         1 (1%)           Concurrent Systemic Therapy         26 (13%)         23 (16%)         15 (28%)           Immunotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control	Head and Neck Squamous Cell Carcinoma	9 (5%)	3 (2%)	6 (12%)	
Metastatic Paraganglioma         3 (2%)         3 (2%)         0 (0%)           Bladder         1 (1%)         1 (1%)         0 (0%)           Adencid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site         0.0%)         5 (9%)         0.0%)           Cervical         22 (10%)         17 (12%)         5 (9%)         0.572           Cervical-Thoracic         8 (5%)         4 (3%)         4 (7%)           Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         26 (13%)         20 (14%)         6 (15%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Redioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         0.001         15 (28%)         38 (70%)	Metastatic Pituitary	1 (1%)	1 (1%)	0 (0%)	
Bladder         1 (1%)         1 (1%)         0 (0%)           Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site	Metastatic Paraganglioma	3 (2%)	3 (2%)	0 (0%)	
Adenoid Cystic Carcinoma         1 (1%)         1 (1%)         0 (0%)           Vertebral Site         0.572           Cervical         22 (10%)         17 (12%)         5 (9%)           Cervical-Thoracic         8 (5%)         4 (3%)         4 (7%)           Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         0 (9%)         3 (3%)         4 (7%)           Concurrent Systemic Therapy         7 (3%)         3 (3%)         4 (7%)           Concurrent Systemic Therapy         28 (20%)         23 (16%)         15 (28%)           Immunotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         51 (9%)         38 (70%)         26 (18%)           Systemic Disease Control <t< td=""><td>Bladder</td><td>1 (1%)</td><td>1 (1%)</td><td>0 (0%)</td><td></td></t<>	Bladder	1 (1%)	1 (1%)	0 (0%)	
Vertebral Site       0.572         Cervical       22 (10%)       17 (12%)       5 (9%)         Cervical-Thoracic       8 (5%)       4 (3%)       4 (7%)         Thoracic       103 (53%)       68 (48%)       35 (65%)         Lumbar       45 (23%)       40 (29%)       5 (9%)         Thoracic-Lumbar       7 (3%)       3 (3%)       4 (7%)         Sacral       9 (6%)       8 (5%)       1 (3%)         Concurrent Systemic Therapy       7 (3%)       3 (3%)       4 (7%)         Chemotherapy       38 (20%)       23 (16%)       15 (28%)         Immunotherapy       26 (13%)       20 (14%)       6 (15%)         Targeted Therapy       20 (10%)       16 (11%)       4 (7%)         Radioactive Iodine       3 (2%)       3 (2%)       0 (0%)         None       107 (55%)       78 (56%)       29 (54%)         Systemic Disease Control <b>0.001</b> Stable       153 (79%)       115 (82%)       38 (70%)         Progression       134 (69%)       107 (76%)       27 (50%)         Systemic Disease Control <b>* * *</b> Systemic Disease Control <b>* * *</b>	Adenoid Cystic Carcinoma	1 (1%)	1 (1%)	0 (0%)	
Cervical         22 (10%)         17 (12%)         5 (9%)           Cervical-Thoracic         8 (5%)         4 (3%)         4 (7%)           Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         7 (3%)         23 (16%)         1 5 (28%)           Immunotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (5%)         78 (56%)         29 (54%)           Systemic Disease Control         0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score	Vertebral Site				0.572
Cervical-Thoracic         8 (5%)         4 (3%)         4 (7%)           Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         9 (6%)         23 (16%)         15 (28%)           Immunotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radicactive Iodine         3 (2%)         3 (2%)         0 (0%)           None         105 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         53 (79%)         115 (82%)         38 (70%)           Progression         513 (79%)         15 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score	Cervical	22 (10%)	17 (12%)	5 (9%)	
Thoracic         103 (53%)         68 (48%)         35 (65%)           Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         26 (13%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive Iodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         105 (28%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score         0.001         27 (50%)            134 (69%)         107 (76%)         27 (50%)            133 (24%)         33 (24%)         27 (50%)	Cervical-Thoracic	8 (5%)	4 (3%)	4 (7%)	
Lumbar         45 (23%)         40 (29%)         5 (9%)           Thoracic-Lumbar         7 (3%)         3 (3%)         4 (7%)           Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         9 (6%)         23 (16%)         15 (28%)           Chemotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         00%         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score         0.001         27 (50%)            134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Thoracic	103 (53%)	68 (48%)	35 (65%)	
Thoracic-Lumbar       7 (3%)       3 (3%)       4 (7%)         Sacral       9 (6%)       8 (5%)       1 (3%)         Concurrent Systemic Therapy       38 (20%)       23 (16%)       15 (28%)         Immunotherapy       38 (20%)       20 (14%)       6 (15%)         Immunotherapy       20 (10%)       16 (11%)       4 (7%)         Targeted Therapy       20 (10%)       16 (11%)       4 (7%)         Radioactive lodine       3 (2%)       3 (2%)       0 (0%)         None       107 (55%)       78 (56%)       29 (54%)         Systemic Disease Control       0001       115 (82%)       38 (70%)         Progression       41 (21%)       25 (18%)       16 (30%)         Spinal Instability Neoplastic Score       0003 (33 (24%)       27 (50%)          134 (69%)       107 (76%)       27 (50%)         >7       60 (31%)       33 (24%)       27 (50%)	Lumbar	45 (23%)	40 (29%)	5 (9%)	
Sacral         9 (6%)         8 (5%)         1 (3%)           Concurrent Systemic Therapy         0.540         0.540           Chemotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         0.001         0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score         0.001         0.011            134 (69%)         107 (76%)         27 (50%)            0.33 (24%)         27 (50%)         0.011	Thoracic-Lumbar	7 (3%)	3 (3%)	4 (7%)	
Concurrent Systemic Therapy         0.540           Chemotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control	Sacral	9 (6%)	8 (5%)	1 (3%)	
Chemotherapy         38 (20%)         23 (16%)         15 (28%)           Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Racioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control          0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score          0.001            134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Concurrent Systemic Therapy				0.540
Immunotherapy         26 (13%)         20 (14%)         6 (15%)           Targeted Therapy         20 (10%)         16 (11%)         4 (7%)           Racioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control           0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score          0.001            134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Chemotherapy	38 (20%)	23 (16%)	15 (28%)	
Targeted Therapy       20 (10%)       16 (11%)       4 (7%)         Radioactive lodine       3 (2%)       3 (2%)       0 (0%)         None       107 (55%)       78 (56%)       29 (54%)         Systemic Disease Control	Immunotherapy	26 (13%)	20 (14%)	6 (15%)	
Radioactive lodine         3 (2%)         3 (2%)         0 (0%)           None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control          0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score          0.001            134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Targeted Therapy	20 (10%)	16 (11%)	4 (7%)	
None         107 (55%)         78 (56%)         29 (54%)           Systemic Disease Control         0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score         0.001         0.001            134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Radioactive Iodine	3 (2%)	3 (2%)	0 (0%)	
Systemic Disease Control         0.001           Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score	None	107 (55%)	78 (56%)	29 (54%)	
Stable         153 (79%)         115 (82%)         38 (70%)           Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score	Systemic Disease Control				0.001
Progression         41 (21%)         25 (18%)         16 (30%)           Spinal Instability Neoplastic Score         0.001 =7</td 134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Stable	153 (79%)	115 (82%)	38 (70%)	
Spinal Instability Neoplastic Score         0.001 =7</td 134 (69%)         107 (76%)         27 (50%)           >7         60 (31%)         33 (24%)         27 (50%)	Progression	41 (21%)	25 (18%)	16 (30%)	
=7</td 134 (69%)     107 (76%)     27 (50%)       >7     60 (31%)     33 (24%)     27 (50%)	Spinal Instability Neoplastic Score				0.001
>/60 (31%)33 (24%)27 (50%)	=7</td <td>134 (69%)</td> <td>107 (76%)</td> <td>27 (50%)</td> <td></td>	134 (69%)	107 (76%)	27 (50%)	
	>/	60 (31%)	33 (24%)	27 (50%)	

(Continued)

#### TABLE 1 | Continued

Bilsky Grade				0.001
1a/b	118 (61%)	98 (70%)	20 (37%)	
1c	24 (13%)	20 (14%)	4 (7%)	
2	29 (14%)	15 (10%)	14 (26%)	
3	23 (12%)	7 (6%)	16 (30%)	
Reason for SBRT				
Oligometastasis	21 (11%)	10 (7%)	11 (20%)	
Oligoprogression	17 (9%)	17 (12%)	0 (0%)	
Radioresistant Histology	86 (44%)	70 (50%)	16 (30%)	
Pain	70 (36%)	43 (31%)	27 (50%)	

BED, biologically effective dose; \*BED10; \*\*BED2; PTV, planning target volume. bold values achieved statistical significance.

## Feasibility of Treatment Delivery and Dosimetry

For patients with  $\geq 3$  vs. 1–2 contiguous treated levels, the median prescribed dose (27 vs. 27 Gy), prescribed dose to the tumor in BED (51 vs. 51 Gy), minimum dose to the PTV in BED (28 vs. 31 Gy), mean dose to the PTV in BED (54 vs. 54 Gy), D95% in BED (51 vs. 51 Gy), and D90% in BED (52 vs. 52 Gy) were similar, with all p values nonsignificant. The median max spinal cord point dose in BED was similar between patients with  $\geq 3$  vs. 1–2 contiguous treated levels (57 vs. 46, p = 0.326). The median max cauda point dose in BED was similar between patients with  $\geq 3$  vs. 1-2 contiguous treated levels (58 vs. 79, p = 0.327). For patients with  $\geq$ 3 contiguous treated levels, the range of max point spinal cord doses, by BED, was 10-114 Gy, and the range of max point cauda equina doses was 31-94 Gy. The maximum spinal cord point BED of 114 Gy occurred in the treatment of a patient with a high Bilsky grade who was not able to undergo spinal separation surgery. Coverage of at least 95% of the PTV with at least 95% prescription dose was similar between groups (96% 1–2 levels vs. 89%  $\geq$ 3 levels, p = 0.078). Of note, 10 patients had 4-7 contiguous levels treated with a median follow-up of 15.6 months (range: 1-52) (Table 4). In these most complex treatment scenarios, 70% of treatment plans resulted in coverage of at least 95% of the PTV with at least 95% of the prescription dose while still respecting the constraints of organs at risk. In patients with  $\geq$ 3 treated levels, early recurrences were found in several patients with high-grade sarcomas, chondrosarcoma, and triple-negative breast cancer.

### Acute and Chronic Toxicities

There was no significant difference between the two groups in terms of acute toxicities (18% vs. 21%), which were limited to grade 1–2 fatigue, grade 1 dermatitis, grade 1 nausea, and grade 1 pain flare. There were no grade 3 or higher acute events. Pain flare incidence was 5.5% in the whole cohort in which patients required steroids  $\pm$  opioids. Regarding chronic toxicity, of the 131 courses of definitive spine SBRT without surgical intervention, 11 cases (8.4%) presented with progressive/new vertebral compression fracture (VCF) over a median follow-up of 15 months. There was no difference between patients with 1–2 (8%) and  $\geq$ 3 treated levels (10%) in terms of progressive/new VCF (OR 1.18, CI 0.236–5.902, p = 0.839). There were no events of radiation-induced myelopathy, radiculopathy, or plexopathy in either group, and there were no reported grade 3 and above late toxicities.





**TABLE 2** | Univariate analysis examining for variables associated with improved local control in patients with  $\geq$ 3 contiguous treated levels using a proportional hazards model.

Variable	1-Year Local Control	p value
Age		
≤60	89%	0.882
>60	88%	
Gender		
Men	91%	0.278
Women	75%	
Surgery		
Vertebrectomy	80%	0.148
Laminectomy	90%	
None	95%	
Prescription BED*		
≥51.3Gy	84%	0.869
<51.3Gy	87%	
PTV Minimum BED*		
≥28Gy	82%	0.834
<28Gy	87%	
PTV Mean BED*		
≥55.13Gy	81%	0.492
<54.13Gy	90%	
PTV D90% BED*		
≥52Gy	82%	0.654
<52Gy	89%	
PTV D95% BED*		
≥51.3Gy	82%	0.632
<51.3Gy	90%	
PTV Coverage by Prescription Dos	se	
≥95%	85%	0.706
		(Continued)

TABLE 2 | Continued

<95% 83% Treated Volume <150cc 90% ≥150cc 79% Systemic Disease Control Stable 92%	0.292
Treated Volume <150cc 90% ≥150cc 79% Systemic Disease Control Stable 92%	0.292
<150cc 90% ≥150cc 79% Systemic Disease Control Stable 92%	0.292
≥150cc 79% Systemic Disease Control Stable 92%	
Systemic Disease Control Stable 92%	
Stable 92%	
	0.090
Progressive 54%	
Spinal Instability Neoplastic Score	
≤7 96%	0.122
>7 69%	
Bilsky	
Grade 1a-c 96%	0.171
Grade 2–3 71%	
Fractionation	
Single 67%	0.270
Multi 86%	
Histopathology	
Renal Cell Carcinoma 93%	0.329
Rest 81%	

BED\*, biologically effective dose 10; PTV, planning target volume.

# DISCUSSION

This study represents one of the first analyses to suggest that SBRT to  $\geq$ 3 contiguous spinal levels may be feasible and similarly safe and effective to treatment to 1–2 levels. These findings have strong clinical relevance because a recent phase III trial demonstrated improved treatment response with SBRT with

**TABLE 3** | Multivariate analysis examining for variables associated with improved local control in patients with  $\geq$ 3 contiguous treated levels using a proportional hazards model.

Variable	Hazard Ratio	95% Confidence Interval	p value
	1 205	0.560, 2.105	0.520
Aye Gender	2 734	1.047-7.142	0.520
Surgery vs. None	1 708	0.486-6.007	0.404
Prescribed BED*	0.357	0.084–1.519	0.163
Planning Target Volume D90% BED*	1.120	0.304-4.132	0.865
Treatment Volume	0.693	0.269-1.787	0.448
Histopathology	1.022	0.946-1.105	0.578
Spinal Instability Neoplastic Score	1.442	0.962-2.162	0.077
Bilsky	1.234	0.630-2.416	0.539
Systemic Disease Control	4.154	1.667–10.355	0.002

BED\*, biologically effective dose 10; CI, confidence interval; HR, hazard ratio; D90%, minimum dose received by 90% of the planning target volume; D95%, minimum dose received by 95% of the planning target volume.

bold values achieved statistical significance.

Case	Site	Dose (Gy/ fx)	NTL	Minimum dose (BED10)	Mean dose (BED10)	D90% (BED10)	SC/CE max dose (BED2)	Coverage	Number of CBCT/ course
1	Т	25/5	4	35.4	43.1	38.4	114.6	≥95%	5
2	С	27.5/5	4	19.8	44.5	42.0	28.13	<95%	6
3	Т	25/5	4	29.6	39.3	38.2	66.72	≥95%	10
4	T-L	27/3	5	14.9	51.3	49.2	32.06	<95%	5
5	L	27/3	5	36.7	54.1	51.9	56.78	≥95%	6
6	Т	25/5	5	13.1	40.6	36.5	21.53	<95%	6
7	C-T	25/5	5	10.8	41.0	38.8	50.03	≥95%	6
8	C-T	25/5	6	16.5	40.8	38.3	10.27	≥95%	9
9	Т	25/5	6	14.8	40.0	37.5	30.48	≥95%	7
10	Т	25/5	7	28.9	39.4	38.2	71.7	≥95%	7

TABLE 4 | Plan and treatment delivery characteristics for patients with 4–7 contiguous treated levels.

BED, biologically effective dose; C, cervical spine; CBCT, cone beam CT; CE, cauda equina; T, thoracic spine; L, lumbar spine; NTL, number treated levels; SC, spinal cord.

respect to conventional EBRT (15), but patients with multilevel disease have been previously considered to be suboptimal candidates for SBRT due to feasibility concerns. Regarding feasibility, coverage of at least 95% of the PTV with at least 95% prescription dose was achievable in 89% of patients with  $\geq$ 3 treated contiguous levels, no different from the rate seen for patients with 1–2 treated levels. While repositioning with reimaging was required for some fractions, particularly for patients with 4 or more involved levels, there were no issues with treatment delivery.

Additionally, treatment for these complex patients was similarly effective to SBRT to 1–2 levels in both our patients and historical controls. Multiple studies have demonstrated that 1-year control rates with spine SBRT of 71%–97% may be superior to tumor control with conventional radiotherapy (2–5, 16–19). Our 1-year LF rate of 12% for the entire cohort (1–7 treated levels) was similar to these historical controls. Most importantly, our 1-year LF rate for those patients with  $\geq$ 3 treated levels was just 16%, which was not statistically different from the rate of LF for patients receiving treatment to 1–2 levels. While patients with  $\geq$ 3 treated levels were more likely to undergo surgery or have breast or prostate histologies, this imbalance likely does not explain the excellent rates of LC in this subcohort, as these variables did not significantly predict LC on UVA or MVA. While infrequent, the failures in this subgroup were

primarily driven by the preponderance of patients with extremely radioresistant histologies such as sarcoma. These findings are similar to those from Beeler et al. (20) showing 1year LC rates for single-level and multilevel SBRT of 95% vs. 85% (p = 0.11). On MVA, progressive systemic disease at the time of SBRT was significantly associated with inferior LC. This relationship may be because poor systemic disease control portends a more treatment-resistant disease process. Additionally, female gender was significantly associated with inferior LC. Given the almost borderline p value for this variable, these results are likely attributable to chance.

Notably, SBRT to  $\geq$ 3 levels did not result in increased acute or chronic toxicity with respect to our patients with fewer treated levels or to historical controls. While SBRT is known to increase the risk of VCF to about 15% and radiation-induced myelopathy can also be a concern (16, 21–23), the risk of progressive/new VCF in our patients with  $\geq$ 3 levels was just 9.5% with a 0% rate of radiation-induced myelopathy. In our study, there was no statistically significant difference between groups in terms of acute or late toxicities and there were no high-grade toxicities regardless of the number of contiguous treated levels. With this excellent durable LC and low incidence of side effects, multilevel contiguous SBRT may be a good option for appropriately selected patients with spine metastases.

Multilevel SBRT for Spine Metastases

Some limitations of this approach and this analysis should be considered. Due to differences in group size, match-pair analysis was not feasible, and there may be unaccounted for differences between groups. However, besides systemic disease control and gender, no variables were significant predictors of LF on MVA, suggesting that the inability to conduct match-pair analysis may have a relatively minimal impact. Spine SBRT, particularly multilevel, poses unique barriers to reliable daily setup and accurate treatment delivery. A sharp dose falloff is required close to critical structures with the potential for around 2-Gy perturbation to the Dmax delivered to the spinal cord if there is even a 1-mm vertical misalignment (9). The utilization of a headrest for patient comfort with a thermoplastic head and neck mask for immobilization for cervical and upper thoracic spine SBRT can result in an air gap with cervical and upper thoracic spine curvature being difficult to reproduce on a daily basis (9). However, modern equipment such as 6-DOF couches can correct these translational and rotational errors (24, 25). This capability, in combination with full-body immobilization and CBCT, has led to the achievement of submillimeter accuracy for treatment delivery in about 98% of SBRT cases, particularly for treatments delivered to T2-S5 (9). Thus, at our institution, we used a 0-mm expansion from CTV to PTV and 2-mm PRV expansion around the spinal cord/cauda equina for both postoperative and definitive spine SBRT patients. However, another retrospective study noted mean translational errors of 0.5 mm with a standard deviation of 0.5 mm for multilevel spine SBRT (26). Thus, although our rates of LF were excellent despite no PTV expansion, we acknowledge that PTV expansions should be considered depending upon institutional comfort with setup reproducibility. Additionally, the best candidates for SBRT with multilevel disease are likely to be well-performing patients eligible for debulking and with excellent systemic therapy options; otherwise, the potential benefit in improved durable

### REFERENCES

- Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, et al. The NOMS Framework: Approach to the Treatment of Spinal Metastatic Tumors. Oncologist (2013) 18:744–51. doi: 10.1634/theoncologist.2012-0293
- Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for Spinal Metastases: Clinical Experience in 500 Cases From a Single Institution. *Spine* (*Phila Pa 1976*) (2007) 32:193–9. doi: 10.1097/01.brs.0000251863.76595.a2
- Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, et al. High-Dose, Single-Fraction Image-Guided Intensity-Modulated Radiotherapy for Metastatic Spinal Lesions. *Int J Radiat Oncol Biol Phys* (2008) 71:484–90. doi: 10.1016/j.ijrobp.2007.11.046
- Yamada Y, Katsoulakis E, Laufer I, Lovelock M, Barzilai O, McLaughlin LA, et al. The Impact of Histology and Delivered Dose on Local Control of Spinal Metastases Treated With Stereotactic Radiosurgery. *Neurosurg Focus* (2017) 42:E6. doi: 10.3171/2016.9.FOCUS16369
- Rades D, Cacicedo J, Conde-Moreno AJ, Segedin B, Lomidze D, Ciervide R, et al. Comparison of 5 × 5 Gy and 10 × 3 Gy for Metastatic Spinal Cord Compression Using Data From Three Prospective Trials. *Radiat Oncol* (2021) 16:7. doi: 10.1186/s13014-020-01737-7
- Blakaj DM, Palmer JD, Dibs K, Olausson A, Bourekas EC, Boulter D, et al. Postoperative Stereotactic Body Radiotherapy for Spinal Metastasis and Predictors of Local Control. *Neurosurgery* (2021) 88:1021–7. doi: 10.1093/ neuros/nyaa587

LC with this approach, with respect to standard palliative techniques, may not be meaningful. Additional limitations primarily stem from the study's retrospective nature and include potential patient selection biases.

In summary, in appropriately selected patients, spine SBRT to 3–7 contiguous vertebral levels is feasible and may offer high rates of LC with minimal toxicity. As a result, the benefits of spine SBRT may be extendable to patients with multilevel disease who have been considered more appropriate for conventional EBRT. A prospective evaluation of this approach is warranted.

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors without undue reservation.

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Ohio State University Institutional Review Board. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

## AUTHOR CONTRIBUTIONS

KD, DMB: first authors. RP, AO, EB, DB, AA, EC, WM, PM, ET, HL, JG, RR, EM, TS, RL, AC, and JE: contributors. JP: senior author. All authors contributed to the article and approved the submitted version.

- Ryu S, Pugh SL, Gerszten PC, Yin F-F, Timmerman RD, Hitchcock YJ, et al. RTOG 0631 Phase 2/3 Study of Image Guided Stereotactic Radiosurgery for Localized (1-3) Spine Metastases: Phase 2 Results. *Pract Radiat Oncol* (2014) 4:76–81. doi: 10.1016/j.prro.2013.05.001
- Wang H, Shiu A, Wang C, O'Daniel J, Mahajan A, Woo S, et al. Dosimetric Effect of Translational and Rotational Errors for Patients Undergoing Image-Guided Stereotactic Body Radiotherapy for Spinal Metastases. *Int J Radiat Oncol Biol Phys* (2008) 71:1261–71. doi: 10.1016/j.ijrobp.2008.02.074
- Wang X, Zhao Z, Luo D, Yang JN, Yang J, Chang EL, et al. Submillimeter Alignment of More Than Three Contiguous Vertebrae in Spinal SRS/SBRT With 6-Degree Couch. J Appl Clin Med Phys (2017) 18:225–36. doi: 10.1002/ acm2.12153
- Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, et al. International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic Radiosurgery. *Int J Radiat Oncol Biol Phys* (2012) 83:e597–605. doi: 10.1016/j.ijrobp.2012.03.009
- Redmond KJ, Robertson S, Lo SS, Soltys SG, Ryu S, McNutt T, et al. Consensus Contouring Guidelines for Postoperative Stereotactic Body Radiation Therapy for Metastatic Solid Tumor Malignancies to the Spine. *Int J Radiat Oncol Biol Phys* (2017) 97:64–74. doi: 10.1016/j.ijrobp. 2016.09.014
- Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic Body Radiation Therapy: The Report of AAPM Task Group 101. *Med Phys* (2010) 37:4078–101. doi: 10.1118/1.3438081

- Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn M-J, et al. Response Assessment After Stereotactic Body Radiotherapy for Spinal Metastasis: A Report From the SPIne Response Assessment in Neuro-Oncology (SPINO) Group. *Lancet Oncol* (2015) 16:e595–603. doi: 10.1016/ S1470-2045(15)00166-7
- Schemper M, Smith TL. A Note on Quantifying Follow-Up in Studies of Failure Time. *Control Clin Trials* (1996) 17:343-6. doi: 10.1016/0197-2456 (96)00075-x
- Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, et al. Stereotactic Body Radiotherapy Versus Conventional External Beam Radiotherapy in Patients With Painful Spinal Metastases: An Open-Label, Multicentre, Randomised, Controlled, Phase 2/3 Trial. *Lancet Oncol* (2021) 22:1023–33. doi: 10.1016/S1470-2045(21)00196-0
- Thibault I, Al-Omair A, Masucci GL, Masson-Côté L, Lochray F, Korol R, et al. Spine Stereotactic Body Radiotherapy for Renal Cell Cancer Spinal Metastases: Analysis of Outcomes and Risk of Vertebral Compression Fracture. J Neurosurg Spine (2014) 21:711–8. doi: 10.3171/2014.7.SPINE13895
- Balagamwala EH, Angelov L, Koyfman SA, Suh JH, Reddy CA, Djemil T, et al. Single-Fraction Stereotactic Body Radiotherapy for Spinal Metastases From Renal Cell Carcinoma. J Neurosurg Spine (2012) 17:556–64. doi: 10.3171/ 2012.8.SPINE12303
- Heron DE, Rajagopalan MS, Stone B, Burton S, Gerszten PC, Dong X, et al. Single-Session and Multisession CyberKnife Radiosurgery for Spine Metastases-University of Pittsburgh and Georgetown University Experience. *J Neurosurg Spine* (2012) 17:11–8. doi: 10.3171/2012.4.SPINE11902
- Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, et al. Phase I/ II Study of Stereotactic Body Radiotherapy for Spinal Metastasis and its Pattern of Failure. J Neurosurg Spine (2007) 7:151–60. doi: 10.3171/SPI-07/08/151
- Beeler WH, Speth KA, Broderick MT, Jairath NK, Ballouz D, Gharzai LA, et al. Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy. *Neurosurgery* (2020) 86:E164–72. doi: 10.1093/neuros/nyz348
- Cunha MVR, Al-Omair A, Atenafu EG, Masucci GL, Letourneau D, Korol R, et al. Vertebral Compression Fracture (VCF) After Spine Stereotactic Body Radiation Therapy (SBRT): Analysis of Predictive Factors. *Int J Radiat Oncol Biol Phys* (2012) 84:e343–349. doi: 10.1016/j.ijrobp.2012.04.034

- Gibbs IC, Patil C, Gerszten PC, Adler JR, Burton SA. Delayed Radiation-Induced Myelopathy After Spinal Radiosurgery. *Neurosurgery* (2009) 64:A67– 72. doi: 10.1227/01.NEU.0000341628.98141.B6
- Benzil DL, Saboori M, Mogilner AY, Rocchio R, Moorthy CR. Safety and Efficacy of Stereotactic Radiosurgery for Tumors of the Spine. J Neurosurg (2004) 101(Suppl 3):413-8. doi: 10.3171/jns.2004.101 .supplement3.0413
- 24. Stewart D. A Platform With Six Degrees of Freedom. *Proc Instit Mechanical Eng* (1965) 180:371–86. doi: 10.1243/PIME\_PROC\_1965\_180\_029\_02
- Hornick DC, Litzenberg DW, Lam KL, Balter JM, Hetrick J, Ten Haken RK. A Tilt and Roll Device for Automated Correction of Rotational Setup Errors. *Med Phys* (1998) 25:1739–40. doi: 10.1118/1.598355
- Chang JH, Sangha A, Hyde D, Soliman H, Myrehaug S, Ruschin M, et al. Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy. *Technol Cancer Res Treat* (2017) 16:231–7. doi: 10.1177/1533034616681674

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Dibs, Blakaj, Prasad, Olausson, Bourekas, Boulter, Ayan, Cochran, Marras, Mageswaran, Thomas, Lee, Grecula, Raval, Mendel, Scharschmidt, Lonser, Chakravarti, Elder and Palmer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.